CQDSA in Evaluation of Prognosis After EVAR

Status Completed

Clinical Trial Summary

Re-hospitalization or re-intervention is sometimes necessary to treat type I and type III endoleaks after EVAR for its persistent increasing of pressure in aneurysm lumen. Color-coded quantitative digital subtraction angiography (CQDSA) provides an easy and quick way to post-process the traditional digital subtraction angiography (DSA) which converts the peak time of the maximal contrast medium intensity into a single polychromatic image. With the help of CQDSA, a quantitative evaluation of the endoleak hemodynamics and a risk analysis of the type I or type III endoleak could be performed during the EVAR procedure. This approach may offer an objective assessment of the needs for immediate re-intervention, conservative therapy or treatment endpoint in the future.

Clinical Trial Description

Intra-procedural DSA series are transferred to a research workstation to generate the color-coded images and make quantitative measurements. Region of interest (ROI) measurements are performed equivalently in the endoleak and the aorta after the image generation. There are three kinds of ROIs including a small circle area with the shortest time to peak, a circle area with peak contrast intensity and the whole endoleak area. The ROI and a reference at the same latitude within the aorta are selected to undergo measurement which reflected the endoleak hemodynamics of the endoleak to the utmost extent.

The following parameters will be acquired through the CQDSA for analysis.

1. Time-versus-ROI contrast intensity graph. The graph contains one endoleak ROI flow curve and one reference aortic flow curve (Ref). The x-axis shows time from 0 second to the maximum frame time of the image. The y-axis shows the sum of pixel intensities, namely total contrast, representing the contrast concentration within the ROI.

2. ROI Peak/Ref Peak. It is the ratio of intensity peak between the endoleak and the reference in the aorta.

3. ROI TTP (Time to peak). Peak time of ROI in the vicinity of endoleak entry.

4. ROI AUC/Ref AUC. Area under curve (AUC) is calculated through Time-versus-ROI contrast intensity graph. The parameter here is the ratio of ROI AUC in endoleak to the reference. ;

Study Design

Observational Model: Case Control, Time Perspective: Prospective

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02016131
Study type	Observational
Source	Shanghai Zhongshan Hospital
Contact
Status	Completed
Phase	N/A
Start date	January 2012
Completion date	March 2015

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03657979` - TAP-Block in Abdominal Aortic Surgery	Phase 4
Enrolling by invitation	`NCT01465425` - Extracolonic Findings on Computed Tomography (CT) Colonography
Completed	`NCT02845167` - Effect of Preoperative Exercise on Postoperative Outcome in AAA Patients: Pilot Study	N/A
Not yet recruiting	`NCT00358085` - NExT ERA: National Expertise Based Trial of Elective Repair of Abdominal Aortic Aneurysms: A Pilot Study	Phase 3
Terminated	`NCT00118573` - Comparison of Surveillance Versus Aortic Endografting for Small Aneurysm Repair	Phase 4
Completed	`NCT04792411` - Adherence and Acceptability of a Remote, Home-based, Pre-surgery Programme for Patients Undergoing Abdominal Aortic Aneurysm Surgery	N/A
Completed	`NCT04930172` - TOtal tRansfemoral branCHed endovasCular tHoracoabdominal Aortic Repair Registry
Withdrawn	`NCT02995642` - Targeted PET/CT and PET/MRI Imaging of Vascular Inflammation	Phase 2
Completed	`NCT01980901` - Post-Approval Study of the Ovation™/Ovation Prime™ Abdominal Stent Graft System
Active, not recruiting	`NCT01698671` - InterGard Synergy Post-Marketing Surveillance Study	N/A
Enrolling by invitation	`NCT00831870` - EndoSure Sensor for Long-term Follow-up After Endovascular AAA Repair	N/A
Recruiting	`NCT05972018` - Liposomal Bupivacaine/Bupivacaine in RS Blocks vs. Ropivacaine in RS Blocks And Catheters	Phase 4
Not yet recruiting	`NCT02997618` - The AAA Get Fit Trial: A Pilot Randomised Controlled Trial of Community Based Exercise in Patients With Abdominal Aortic Aneurysms	N/A
Active, not recruiting	`NCT02907762` - Aorfix Intelliflex First in Human Study
Completed	`NCT00349947` - Exercise Therapy to Treat Adults With Abdominal Aortic Aneurysms	Phase 1
Completed	`NCT04080557` - Abdominal Aortic Aneurysm Patients Remain at Risk for Delirium on the Surgical Ward After Intensive Care Unit Dismissal
Recruiting	`NCT05484115` - Comparison of EVAR and ESAR for Infrarenal Aortic Aneurysms With a Wide Proximal Neck	N/A
Recruiting	`NCT04503395` - ShOrt neCK AAA RAndomized Trial - ESAR and FEVAR: SOCRATES	N/A
Completed	`NCT02867501` - Venous Distension in Patients With Aneurysmatic Arterial Disease	N/A
Recruiting	`NCT02345590` - Eplerenone in the Management of Abdominal Aortic Aneurysms	Phase 4

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.